Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgery
Not Applicable
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0000696
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 228
Inclusion Criteria
normal renal function (serum creatinine < 1.3 mg/dl)
-anemic patient (Hgb < 13 g/dl in men, Hgb < 12 g/dl in women accoridng to World Health Organization criteria)
-elective surgery
-20 years old or more than 20 years old
-patient who agree to participate the present clinical study voluntarily
Exclusion Criteria
-non-animic patient ( Hgb = 13 g/dl in men, Hgb = 12 g/dl in women)
-uncontrolled hypertension ( diastolic blood presusre > 100 mmHg)
-platelet > 450,000/mm3
-history of thromboembolism
-concomitant cancer
-chronic use of erythropoietin
-patient who disagree to paricipate the present study voluntarily
-emergency surgery
-chronic kidney disease or serum creatinine = 1.3 mg/dl
-preoperative inotropic support
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum creatinine
- Secondary Outcome Measures
Name Time Method cardiovascular function by SOFA (sequential organ failure assessment) score